LENZ Therapeutics (LENZ) Common Equity (2020 - 2026)
LENZ Therapeutics (LENZ) posted quarterly Common Equity of $246.5 million for Q1 2026, up 28.37% year-over-year from $192.0 million in Q1 2025, and down 13.31% quarter-over-quarter from $284.3 million in Q4 2025.
LENZ Therapeutics (LENZ) Common Equity (2020 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Common Equity for 7 consecutive years, with $246.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 28.37% year-over-year to $246.5 million; the TTM figure through Mar 2026 stood at $246.5 million (up 28.37% YoY), while the FY2025 annual figure was $284.3 million, up 39.32% from the prior year.
- Common Equity fell to $246.5 million in Q1 2026 per LENZ's latest filing, from $284.3 million in the prior quarter.
- Across five years, Common Equity topped out at $361.3 million in Q1 2022 and bottomed at -$92.7 million in Q4 2023.
- Historically, Common Equity has averaged $157.4 million across 5 years, with a median of $198.2 million in 2024.
- Annual changes were most pronounced in 2023 — Common Equity plunged 283.6% — and 2024, when it soared 640.29%.
- LENZ Therapeutics' Common Equity stood at -$24.2 million in 2022, then slumped by 283.6% to -$92.7 million in 2023, then soared by 320.13% to $204.1 million in 2024, then surged by 39.32% to $284.3 million in 2025, then decreased by 13.31% to $246.5 million in 2026.
- Business Quant data shows LENZ's Common Equity at $246.5 million in Q1 2026, $284.3 million in Q4 2025, and $193.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.14 Bn | 132.29 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 87.02 Bn | 79.03 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.12 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.84 Bn | 55.70 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.06 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.49 Bn | 28.18 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.78 Bn | 10.38 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.14 Bn | 26.31 Bn | - | 9.79 Bn |
| 10 | LENZ Therapeutics | 148.63 Mn | 148.63 Mn | 5.21 Mn | 219.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 219.26 Mn |
| Mar 31, 2026 | 246.49 Mn |
| Dec 31, 2025 | 284.34 Mn |
| Sep 30, 2025 | 193.93 Mn |
| Jun 30, 2025 | 206.37 Mn |
| Mar 31, 2025 | 192.01 Mn |
| Dec 31, 2024 | 204.08 Mn |
| Sep 30, 2024 | 215.28 Mn |
| Jun 30, 2024 | 192.92 Mn |
| Mar 31, 2024 | 198.17 Mn |
| Dec 31, 2023 | -92.71 Mn |
| Sep 30, 2023 | -69.57 Mn |
| Jun 30, 2023 | -51.21 Mn |
| Mar 31, 2023 | -36.68 Mn |
| Dec 31, 2022 | -24.17 Mn |
| Sep 30, 2022 | 316.45 Mn |
| Jun 30, 2022 | 338.46 Mn |
| Mar 31, 2022 | 361.30 Mn |
| Dec 31, 2021 | 384.05 Mn |
| Sep 30, 2021 | 400.13 Mn |